Phase 2b trial of CC-42344.
Latest Information Update: 22 Mar 2024
At a glance
- Drugs CC 42344 (Primary)
- Indications Influenza A virus infections
- Focus Therapeutic Use
Most Recent Events
- 22 Mar 2024 New trial record
- 19 Mar 2024 According to a Cocrystal Pharma, Inc. media release, the company has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A.